Skip to content

US · ADIL · BIOTECHNOLOGY

Adial Pharmaceuticals, Inc. (ADIL) intrinsic value and stock valuation

$5.05as of 2026-11-21 · Mkt cap 3.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Adial Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ADIL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ADIL’s statements →

Adial Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Glen Allen, VA 23060 adial.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-7.98M
20152025
Free cash flow
-$-6.49M
20152025
Total equity
$5.28M+5.8% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-7.8M-$-8.28M-$-6.89M-$-10.86M-$-19.29M
Net income-$-7.98M-$-13.2M-$-7M-$-12.73M-$-19.42M
EPSd-$-11.91M-$-17.84M-$-116.67M-$-318.25M-$-647.33M
Operating cash flow-$-6.49M-$-6.92M-$-6.81M-$-11.19M-$-11.95M
Capital expenditure$0.00$0.00$6.81M$0.00-$-60K
Free cash flow-$-6.49M-$-6.92M$0.00-$-11.19M-$-12.01M
Total assets$6.8M$5.04M$4.74M$5.73M$7.63M
Total debt$0.00$0.00$0.00$210K$260K
Net debt-$-5.88M-$-3.75M-$-2.83M-$-3.79M-$-5.81M
Total equity$5.28M$4.07M$4.08M$3.28M$3.51M
Cash and short-term investments$5.88M$3.75M$2.83M$4M$6.06M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00-$0.00$0.00$0.00
Research and development expenses$2.62M$3.23M$1.27M$1.95M$8.4M
Selling, general and administrative expenses$5.18M$5.06M$5.62M$8.91M$9.34M
Other expenses$0.00$0.00-$0.00$0.00$1.55M
Operating expenses$7.8M$8.28M$6.89M$10.9M$19.3M
Cost and expenses$7.8M$8.28M$6.89M$10.9M$19.3M
Interest income$150K$180K$70K$60K$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$0.00$60K
Ebitda-$-7.98M-$-13.2M-$-7M-$-10.8M-$-17.69M
Operating income-$-7.8M-$-8.28M-$-6.89M-$-10.86M-$-19.29M
Total other income/expenses, net-$-180K-$-4.91M-$-110K$60K-$-230K
Income before tax-$-7.98M-$-13.2M-$-7M-$-10.8M-$-19.52M
Income tax expense$0.00$0.00$0.00$0.00-$-90K
Net income-$-7.98M-$-13.2M-$-7M-$-12.73M-$-19.42M
Weighted average shares outstanding$670K$740K$60K$40K$30K
Weighted average diluted shares outstanding$670K$740K$60K$40K$30K
Balance sheet
20252024202320222021
Cash and short-term investments$5.88M$3.75M$2.83M$4M$6.06M
Net receivables$40K$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$6.18M$4.06M$3.2M$4.78M$6.46M
Property, plant and equipment, net$0.00$0.00$0.00$240K$300K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$250K
Long-term investments$490K$980K$1.53M$0.00$0.00
Total non-current assets$620K$990K$1.54M$950K$1.17M
Total assets$6.8M$5.04M$4.74M$5.73M$7.63M
Accounts payable$660K$250K$100K$280K$290K
Short-term debt$0.00$0.00$0.00$60K$50K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.4M$980K$650K$1.79M$2.72M
Long-term debt$0.00$0.00$0.00$150K$210K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$120K$0.00$0.00$670K$1.4M
Capital lease obligations$0.00$0.00$0.00$210K$210K
Total liabilities$1.52M$980K$650K$2.46M$4.13M
Common stock$0.00$10K$0.00$0.00$20K
Retained earnings-$-89.97M-$-82M-$-68.8M-$-63.67M-$-50.94M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$5.28M$4.07M$4.08M$3.28M$3.51M
Total investments$490K$980K$1.53M$0.00$0.00
Total debt$0.00$0.00$0.00$210K$260K
Net debt-$-5.88M-$-3.75M-$-2.83M-$-3.79M-$-5.81M
Cash flow statement
20252024202320222021
Net income-$-7.98M-$-13.2M-$-7M-$-12.73M-$-19.42M
Depreciation and amortization$0.00$0.00$0.00$60K$60K
Stock-based compensation$680K$800K$1.75M$3.37M$4.24M
Change in working capital$470K$390K-$-790K-$-1.37M$1.46M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$360K$170K-$-160K$110K-$-350K
Net cash provided by operating activities-$-6.49M-$-6.92M-$-6.81M-$-11.19M-$-11.95M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00-$-60K
Acquisitions, net$0.00$0.00$0.00$0.00$30K
Net cash used for investing activities$150K$0.00$1.5M$0.00-$-30K
Common stock issued$8.47M$4.02M$4.13M$9.12M$11.8M
Common stock repurchased$0.00$0.00-$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.47M$7.85M$4.13M$9.13M$13.6M
Net change in cash$2.13M$920K-$-1.17M-$-2.06M$1.66M
Cash at end of period$5.88M$3.75M$2.83M$4M$6.06M
Operating cash flow-$-6.49M-$-6.92M-$-6.81M-$-11.19M-$-11.95M
Capital expenditure$0.00$0.00$6.81M$0.00-$-60K
Free cash flow-$-6.49M-$-6.92M$0.00-$-11.19M-$-12.01M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Adial Pharmaceuticals, Inc.

        Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

        CEO
        Cary John Claiborne
        Employees
        6
        Beta
        1.43

        Explore

        Frequently asked questions

        What is the intrinsic value of Adial Pharmaceuticals, Inc. (ADIL)?

        InvestorsCraft does not currently publish an intrinsic value for ADIL. How the IC value is calculated.

        Is ADIL undervalued?

        InvestorsCraft does not publish an undervaluation signal for ADIL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.